Lumanity

Overview

Lumanity is the unified Arsenal-backed platform created from a roll-up of legacy firms including Cello Health, BresMed, Guidemark Health, Cyan Health, Zipher Medical Affairs, Endpoint Outcomes, and Clarion Healthcare. Buyers searching those legacy names should evaluate Lumanity as the current global life-sciences value-demonstration and commercialization partner spanning market access, HEOR, real-world evidence, regulatory strategy, medical communications, and AI-enabled stakeholder engagement.

For launch teams, the useful read is breadth: Lumanity can connect access strategy, evidence planning, payer-facing value story, medical communications, and launch-readiness work under one operating model.

The best buyer fit is a pharma or biotech team with a complex evidence and access problem: oncology, rare disease, cell and gene therapy, neuroscience, immunology, or other specialty products where HTA expectations, payer evidence, medical narrative, and stakeholder engagement need to be reconciled before launch.

Market Access Capability Model

The framework below standardizes how Rx Almanac evaluates market-access-consulting capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Lumanity is evaluated as unified Arsenal-backed platform created from a roll-up of legacy firms including Cello Health, BresMed, Guidemark Health, Cyan Health, Zipher Medical Affairs, Endpoint Outcomes, and Clarion Healthcare.

Capability	Buyer should compare	Lumanity readout
Payer landscape and access strategy	Payer segmentation, formulary expectations, coverage barriers, benefit design, and access scenario planning.	Core access strategy. Lumanity reports 50+ payer submissions across 20+ countries annually and is strongest where payer, HTA, medical, and evidence strategy need to stay connected.
Pricing, contracting, and GTN strategy	WAC strategy, rebate design, contracting scenarios, GTN forecasting, channel economics, and net-price risk.	Strategy-led; validate execution depth. Use Lumanity for pricing and value strategy, IRA / EU JCA implications, and payer evidence framing; validate whether the team will also own detailed contracting math, GTN forecasting, and implementation handoffs.
HEOR, value dossiers, and evidence planning	Budget impact, cost-effectiveness, AMCP dossier, evidence gaps, PRO endpoints, and value story.	Core evidence work. HEOR, RWE, value dossiers, outcomes research, and global submission support are central to the profile, reinforced by PHARMO real-world-data depth.
Payer engagement and message testing	Ad boards, mock P&T, payer research, message testing, objection handling, and stakeholder mapping.	Core payer engagement. Lumanity supports payer engagement and message testing, with EMULaiTOR adding synthetic-persona simulation for pre-launch stakeholder scenario testing.
Policy, IRA, Medicaid, and channel strategy	IRA, Medicaid, 340B, Medicare, specialty channel, distribution, and policy-risk implications.	Strong policy-sensitive evidence fit. Public materials emphasize IRA negotiation support and EU JCA / HTA readiness; validate Medicaid, 340B, and channel depth when those are central to the launch.
Launch sequencing and execution support	Cross-functional launch planning, access playbooks, field tools, governance, and implementation support.	Documented / integrated. Lumanity is best suited to launches that need strategy, evidence, medical communications, and stakeholder engagement sequenced together; validate handoffs to hub, field reimbursement, and account-management operators.

Buyer Fit

• Buyer trigger: Use Lumanity when access, evidence generation, medical narrative, and stakeholder engagement are intertwined enough that a narrow pricing boutique or standalone agency would create coordination risk.
• Therapy and product fit: Strongest public fit is oncology, immunology, neuroscience, cell and gene therapy, rare disease, infectious disease, and other specialty products with meaningful payer / HTA scrutiny.
• Commercial fit: Pricing is custom/RFP, so define senior-team commitment, evidence deliverables, data rights, AI governance, and handoff responsibilities in the statement of work.
• Best-fit buyers: Pharma manufacturers and biotechs preparing global or multi-market launches, especially when payer evidence, value story, and medical communications need one plan.
• Contracting diligence: Confirm how much payer input is primary research, how current the evidence assumptions are, and which downstream operators will convert strategy into account, hub, field, and medical-affairs execution.

Differentiators

• Integrated evidence-to-engagement model: Lumanity combines market access strategy, HEOR, RWE, medical communications, regulatory strategy, and commercial engagement rather than forcing buyers to stitch together separate vendors.
• EDAI and GAIL: The Expert-Directed Applied Intelligence platform and GAIL engine give Lumanity a structured AI layer for value demonstration, evidence synthesis, and commercialization workflows.
• ISO 42001 certification: Lumanity’s AI management-system certification is a useful diligence signal for buyers that need responsible-AI governance around medical, evidence, and stakeholder-engagement work.
• RWE depth: PHARMO strengthens the vendor’s real-world-evidence toolkit for outcomes, epidemiology, and access-supporting evidence work.
• Stakeholder simulation: EMULaiTOR gives launch teams a way to stress-test payer, clinician, and patient engagement assumptions before live stakeholder interactions.

RFP Questions

• Which payer inputs are primary research, standing panels, claims/formulary data, or consultant judgment?
• How will pricing, contracting, evidence, medical, and patient-services recommendations be reconciled into one launch plan?
• Which deliverables can be used directly by account teams, field reimbursement, hub, and medical affairs?
• Which team members are the actual senior operators on the work, and what launch analogs have they handled?
• What AI governance, data-rights, review, and audit controls apply to EDAI, GAIL, EMULaiTOR, and any client-provided data?
• Which responsibilities does Lumanity stop: strategy, evidence, message testing, field tools, contracting support, hub handoff, or ongoing access operations?

Recent Activity

• EMULaiTOR launch (February 2026): Released an AI-enabled synthetic-persona platform for simulating high-stakes stakeholder engagement before launch.
• ISO 42001 certification achieved (February 2026): Became the first life sciences value demonstration partner to earn ISO 42001 certification for AI Management Systems.
• BOBI Award finalist (March 2026): Named finalist for Best Patient-Centric Approach for orchestrating a triple-negative breast cancer launch campaign.
• EDAI platform (August 2025): Launched the Expert-Directed Applied Intelligence platform built on GAIL, its purpose-built generative AI engine.
• VIP Framework (September 2025): Introduced a value-demonstration framework for identifying commercialization decision points from development through delivery.
• Parker Institute alliance (May 2025): Partnered with PICI to connect translational immunotherapy research with commercialization and market-access planning.